Management of Non-metastatic Castration Resistant Prostate Cancer (nmCRPC): Putting current evidence into practice
Non metastatic castrate resistant benefit from the addition of drugs that all lead to major clinical improvement in RCT: a major delay in metastasis and a real increased survival. This […]